Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RZLT with free AI briefings, catalyst countdowns, and dilution alerts.

RZLT · Rezolute, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90M Cash on Hand
16.9mo Cash Runway
Follow RZLT by email Get an email when RZLT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RZLT, unsubscribe in one click. Privacy

📣 What RZLT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ersodetug (RZ358) Tumor Hyperinsulinism (Tumor HI) Phase 3 · NCT06881992 Recruiting
Experimental: Group 1 - 50mg RZ402 Diabetic Macular Edema Phase 2 · NCT05712720 Completed
Experimental: Group 2 - 200mg RZ402 Diabetic Macular Edema Phase 2 · NCT05712720 Completed
Experimental: Group 3 - 400mg RZ402 Diabetic Macular Edema Phase 2 · NCT05712720 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RZLT holds $90M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.9M/quarter from operations, an estimated runway of 16.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RZLT files for a raise →

👥 Who Owns RZLT

Insiders 10.8% Other 5%+ holders 15.8% Institutions (200 holders) 73.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA Capital Healthcare Fund, L.P. 5%+ holder (13G) 15,302,186 15.82% 2025-12-11
Young-Jin Kim
Director · +17,000 options
Insider 8,594,336 8.88% 2025-11-19
Dellora Investments LP Institution (13G, 5%+) 5,721,834 5.92% 2026-08-05
PRUDENTIAL FINANCIAL INC Institution (13G, 5%+) 5,344,968 5.53% 2026-09-30
Jennison Associates LLC Institution (13G, 5%+) 5,332,068 5.51% 2026-09-30
Nevan C Elam
CEO, Director · +226,000 options
Insider 605,497 0.63% 2026-07-02
Daron Evans
CFO · +78,000 options
Insider 477,400 0.49% 2026-10-21
Brian Kenneth Roberts
Chief Medical Officer · +87,000 options
Insider 309,351 0.32% 2026-07-02
Wladimir Hogenhuis
Director · +17,000 options
Insider 119,675 0.12% 2025-12-16
Gil M Labrucherie
Director · +17,000 options
Insider 109,072 0.11% 2025-11-19
Sunil Ratilal Karnawat
Chief Commercial Officer · +294,000 options
Insider 79,173 0.08% 2026-09-02
Nerissa Kreher
Director · +17,000 options
Insider 58,576 0.06% 2025-11-19

Share count 96,728,913 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RZLT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RZLT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.